Hepatitis B Virus Surface Antibody Monitor, Post-Transplant, Serum
Use
This test is useful for monitoring serum hepatitis B virus surface antibody levels during intravenous or intramuscular hepatitis B immune globulin therapy to prevent hepatitis B virus reinfection in liver transplant recipients with known previous chronic hepatitis B. It aids in managing HBIG therapy protocols to maintain desired anti-HBs levels post-transplant to minimize the risk of HBV reinfection.
Special Instructions
Not provided.
Limitations
This test is not licensed by the FDA for screening of blood, plasma, and tissue donors. Elecsys Anti-HBs immunoassay results may not be interchangeable with those from other manufacturers. Possible false-positive results can occur due to passive transfer of anti-HBs from blood products or due to interference from high titers of antibodies. Biotin interference is also a concern. Assay performance characteristics for certain specimen types or conditions have not been established.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ECLIA)
Biomarkers
HBs Antigen
Protein
LOINC Codes
- 5193-8 - HBV surface Ab SerPl IA-aCnc
- 5193-8 - HBV surface Ab SerPl IA-aCnc
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.7 mL
Minimum Volume
0.6 mL
Container
Serum gel; Plastic vial for submission
Collection Instructions
Centrifuge blood collection tube per manufacturer's instructions and aliquot serum into a plastic vial.
Patient Preparation
For 24 hours before specimen collection, patient should not take multivitamins or dietary supplements containing biotin.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus, heat-inactivated specimen
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 6 days |
| Frozen | 90 days |